Biotech Series B Investors & VC Firms
900 firms in this list, with a median first check of $550K. 188 of them lead rounds. Generated from verified public data and updated continuously.
What If Ventures
FriscoPre-Seed–Late Stage
1 person
Corner Ventures
New YorkSeed–Late Stage
10 people
Quad Ventures
SeoulPre-Seed–Late Stage
4 people
INP Capital
VancouverSeed–Late Stage
5 people
MPCi (formerly Matrix Partners China)
SingaporeSeed–Growth
11 people
NEOM
RiyadhPre-Seed–Series C
11 people
PacBridge Capital Partners
Hong KongSeed–Growth
5 people
Pivotal Life Sciences
Seed–Late Stage
5 people
Saisei Ventures
CambridgePre-Seed–Growth
5 people
WONIK Investment Partners
SeoulSeries A–Late Stage
11 people
Extens
ParisSeries A–Series B$3.2M – $16.2M
2 people
Health Technology Holding (HTH)
Pre-Seed–Series B$500K – $1M
2 people
Highbury Holdings
SeattleSeed–Series B$100K – $10M
2 people
KittyHawk Ventures
Silicon ValleySeed–Late Stage$250K – $15M
2 people
Lewis & Clark AgriFood
St. LouisSeries A–Late Stage$2M – $10M
2 people
Montis Capital
WarsawSeries A–Growth$1.6M – $5.5M
2 people
New Business Venture Fund
ReykjavíkSeed–Series B$216K – $4.3M
2 people
The Finnish Innovation Fund Sitra
HelsinkiSeed–Late Stage$108K
2 people
VTC Ventures
RoanokePre-Seed–Series B$100K – $5M
6 people
JourneyOne Ventures
BoulderPre-Seed–Growth
1 person
ODYSSEE VENTURE
ParisSeed–Late Stage$1.1M – $11M
1 person
ACORN BIOVENTURES
New YorkSeed–Late Stage
4 people
Cape Fear BioCapital
DurhamPre-Seed–Series B
3 people
Elevat3 Capital
VallettaSeed–Growth$5M – $20M
Related lists
Series B Investors & VC Firms (4094)Biotech Investors & VC Firms (2107)Biotech Seed Investors & VC Firms (1754)Series B Investors & VC Firms in United States (1625)Biotech Series A Investors & VC Firms (1596)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)Healthtech Series B Investors & VC Firms (1216)Fintech Series B Investors & VC Firms (1141)
Data sourced from public filings and firms' own websites — see our methodology.
















